aacr.org· AACR·· 2026-04-22Score60
Clinical Trial Results: Intralesional Nivolumab for Precancerous Oral Lesions
Reading
Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%
In brief
Phase I trial led by Moran Amit (MD Anderson): direct nivolumab injection shrank treated lesions by about 60% on average in 25 of 29 patients, spared surgery, and kept 82.13% of lesions cancer-free at 12 months.
Conference abstracts
Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
Read the abstract →Source: aacr.org · aacr.org